15:41 , Jul 18, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling Mutations in hematopoiesis-associated genes could help predict the risk of AML. Genomic sequencing of 124 patients who later developed AML and 686 healthy volunteers identified associations between the disease and mutations in...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Imetelstat: Additional Phase II data

Additional data from an investigator-sponsored, open-label, U.S. Phase II trial in 33 patients with intermediate-2 or high-risk primary or secondary MF showed that IV 9.4 mg/kg imetelstat led to an ORR of 21%, including 4...
01:08 , Sep 4, 2015 |  BC Extra  |  Clinical News

Geron rises on published Phase II imetelstat data

Geron Corp. (NASDAQ:GERN) climbed $0.40 (13%) to $3.45 on Thursday after data from two Phase II trials of imetelstat ( GRN163L ) to treat essential thrombocythemia (ET) and myelofibrosis (MF) were published in The New...
07:00 , Oct 31, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Additional sex combs like 1 (Asxl1)-mutant mouse model of myelodysplastic syndrome (MDS) Mice transplanted with bone marrow expressing a mutant form of Asxl1 could model...